

Joel N Maslow

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7326806/publications.pdf>

Version: 2024-02-01

20
papers

922
citations

759190

12
h-index

839512

18
g-index

20
all docs

20
docs citations

20
times ranked

1744
citing authors

#	ARTICLE	IF	CITATIONS
1	Techniques for Developing and Assessing Immune Responses Induced by Synthetic DNA Vaccines for Emerging Infectious Diseases. <i>Methods in Molecular Biology</i> , 2022, 2410, 229-263.	0.9	1
2	Characterization of a small molecule modulator of inflammatory cytokine production. <i>Translational Medicine Communications</i> , 2022, 7, .	1.4	0
3	Safety and Immunogenicity of an Anti-Zika Virus DNA Vaccine. <i>New England Journal of Medicine</i> , 2021, 385, e35.	27.0	244
4	Novel suction-based in vivo cutaneous DNA transfection platform. <i>Science Advances</i> , 2021, 7, eabj0611.	10.3	17
5	Zika Virus: A Brief History and Review of Its Pathogenesis Rediscovered. <i>Methods in Molecular Biology</i> , 2020, 2142, 1-8.	0.9	4
6	Zika-Induced Male Infertility in Mice Is Potentially Reversible and Preventable by Deoxyribonucleic Acid Immunization. <i>Journal of Infectious Diseases</i> , 2019, 219, 365-374.	4.0	11
7	Safety and immunogenicity of an anti-Middle East respiratory syndrome coronavirus DNA vaccine: a phase 1, open-label, single-arm, dose-escalation trial. <i>Lancet Infectious Diseases</i> , The, 2019, 19, 1013-1022.	9.1	235
8	Zika Vaccine Development—Current Progress and Challenges for the Future. <i>Tropical Medicine and Infectious Disease</i> , 2019, 4, 104.	2.3	21
9	Severe fever and thrombocytopenia syndrome virus infection: Considerations for vaccine evaluation of a rare disease. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2249-2257.	3.3	5
10	Challenges and solutions in the development of vaccines against emerging and neglected infectious diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2230-2234.	3.3	9
11	Rapid response to an emerging infectious disease — Lessons learned from development of a synthetic DNA vaccine targeting Zika virus. <i>Microbes and Infection</i> , 2018, 20, 676-684.	1.9	25
12	Assay Challenges for Emerging Infectious Diseases: The Zika Experience. <i>Vaccines</i> , 2018, 6, 70.	4.4	4
13	The cost and challenge of vaccine development for emerging and emergent infectious diseases. <i>The Lancet Global Health</i> , 2018, 6, e1266-e1267.	6.3	15
14	Vaccine development for emerging virulent infectious diseases. <i>Vaccine</i> , 2017, 35, 5437-5443.	3.8	28
15	DNA vaccination protects mice against Zika virus-induced damage to the testes. <i>Nature Communications</i> , 2017, 8, 15743.	12.8	90
16	Vaccines for emerging infectious diseases: Lessons from MERS coronavirus and Zika virus. <i>Human Vaccines and Immunotherapeutics</i> , 2017, 13, 2918-2930.	3.3	33
17	In vivo protection against ZIKV infection and pathogenesis through passive antibody transfer and active immunisation with a prMEnv DNA vaccine. <i>Npj Vaccines</i> , 2016, 1, 16021.	6.0	118
18	Concurrent Outbreak of Multidrug-Resistant and Susceptible Subclones of <i>Acinetobacter baumannii</i> Affecting Different Wards of a Single Hospital. <i>Infection Control and Hospital Epidemiology</i> , 2005, 26, 69-75.	1.8	37

#	ARTICLE	IF	CITATIONS
19	Outbreak of <i>Mycobacterium marinum</i> infection among captive snakes and bullfrogs. <i>Zoo Biology</i> , 2002, 21, 233-241.	1.2	16
20	Immune Responses of a Novel Bi-Cistronic SARS-CoV-2 DNA Vaccine Following Intradermal Immunization With Suction Delivery. <i>Frontiers in Virology</i> , 0, 2, .	1.4	9